← Back to Search

Cancer Vaccine

AVOVA-1 for Fallopian Tube Cancer

Phase 2

Waitlist Available

Research Sponsored by Aivita Biomedical, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial is a double-blind study in which approximately 99 study patients will be randomized in a 2:1 ratio to receive either AVOVA-1 or MC. The primary endpoint of this trial is death from any cause with the metric of OS from the date of randomization. PFS will be a secondary endpoint and will be calculated as the time from the date of randomization for treatment until subjective tumor progression or death.

Eligible Conditions

Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Carcinoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Primary Efficacy Endpoint: Overall Survival

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: AVOVA-1Experimental Treatment1 Intervention

Autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells. AVOVA-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.

Group II: MCPlacebo Group1 Intervention

Autologous monocytes will serve as the control arm. MC is admixed with GM-CSF as an adjuvant, prior to injection.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Aivita Biomedical, Inc.Lead Sponsor

7 Previous Clinical Trials

946 Total Patients Enrolled

Robert O Dillman, MDStudy ChairAivita Biomedical, Inc.

7 Previous Clinical Trials

834 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does AVOVA-1 pose any risk to human health?

"There are preliminary safety data for AVOVA-1, resulting in a score of 2. Unfortunately there is no existing clinical evidence that supports the efficacy of this drug yet."

Answered by AI

Are there any vacancies still available in this trial for participants?

"According to clinicaltrials.gov, this medical experiment is no longer recruiting participants; it was initially posted on November 18th, 2017 with its last update occurring in April 21st 2022. Although inactive for new patients, there are 2894 other trials accepting participants at present."

Answered by AI

How many venues are presently hosting this research endeavor?

"As part of this medical trial, 6 different healthcare facilities are operational. These include Scripps Health in La Jolla, Hoag Memorial Hospital Presbyterian in Newport Beach and University of Colorado Hospital - Cancer Center Aurora, as well as 3 more locations."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas

2017. "Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02033616.